NSCLC has become recognized as being a heterogeneous set of diseases (Reck et al., 2013) and, in patients with lung adenocarcinomas, epidermal growth factor receptor (EGFR) mutations are associated with response to EGFR inhibitors. Here, EGFR is linked to lung adenocarcinoma.